Granules India's Gagillapur facility gets 11 observations in USFDA inspection

What happened

Granules India said the USFDA closed an inspection of its Gagillapur finished dosage facility in Hyderabad with a Form FDA 483 listing 11 observations. The October 19 to 30, 2026 inspection was the first since a February 2025 Warning Letter; the company said data integrity and cross-contamination were not cited.

Confirmed

Global impact / market context

A Form FDA 483 lists inspection concerns and can pressure a drugmaker's compliance costs and US sales if not fixed. Because this was the first inspection after a Warning Letter, investors will treat the 11 observations as a test of whether the plant's quality systems have improved.

Analyst inference

Granules says manufacturing and distribution are unaffected and it will respond within 15 business days. How the USFDA judges that response, and whether new observations follow the earlier Warning Letter, will shape perceived regulatory risk for the stock and for other Indian drugmakers selling into the US.

Analyst inference

What to watch

1. The company plans to submit a comprehensive response to the USFDA within the stipulated 15 business days, addressing the 11 observations from the Gagillapur inspection. Confirmed
2. Watch whether Granules discloses the content of its corrective and preventive actions, since promised fixes for investigations, change control and documentation would show how it intends to close the observations. Proposed
3. Track any follow-up USFDA communication or re-inspection of the facility, because a repeat visit or escalation would raise costs and could affect US revenue from this site. Analyst inference

Evidence

• Original source link unavailable